Details of the Drug

General Information of Drug (ID: DMGDC36)

Drug Name

PNU-282987

Synonyms

Benzamide, N-(3R)-1-azabicyclo[222]oct-3-yl-4-chloro-; PNU282987; 123464-89-1; 711085-63-1; PNU 282987; UNII-27M563MU5U; N-(3R)-1-Azabicyclo[222]oct-3-yl-4-chlorobenzamide; CHEMBL177611; 27M563MU5U; Benzamide, N-(3R)-1-azabicyclo(222)oct-3-yl-4-chloro-; CHEMBL554984; PNU-282,987; PNU-282987 free base; SCHEMBL677422; PNU282987HCl; GTPL3988; CHEBI:92508; CTK2H4027; MolPort-023-219-197; MolPort-003-983-664; HMS3268J18; ZINC3990028; BDBM50161764; BDBM50161753; ABP000998; AKOS016339643; AKOS024457037; KS-1399; API0008100; N-((3R)-1-Azabicyclo(222)oct-3-yl)-4-chlorobenzamide hydrochloride; ISIS 25302

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Terminated	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

301.2

Topological Polar Surface Area

Not Available

Rotatable Bond Count

2

Hydrogen Bond Donor Count

2

Hydrogen Bond Acceptor Count

2

Chemical Identifiers

Formula: C14H18Cl2N2O
IUPAC Name: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide;hydrochloride
Canonical SMILES: C1CN2CCC1[C@H](C2)NC(=O)C3=CC=C(C=C3)Cl.Cl
InChI: InChI=1S/C14H17ClN2O.ClH/c15-12-3-1-11(2-4-12)14(18)16-13-9-17-7-5-10(13)6-8-17;/h1-4,10,13H,5-9H2,(H,16,18);1H/t13-;/m0./s1
InChIKey: HSEQUIRZHDYOIX-ZOWNYOTGSA-N

Cross-matching ID

PubChem CID: 11243536
CAS Number: 123464-89-1
TTD ID: D06LKM
VARIDT ID: DR00756

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuronal acetylcholine receptor alpha-7 (CHRNA7)	TTLA931	ACHA7_HUMAN	Antagonist	[2]
TNFA messenger RNA (TNF mRNA)	TTC97NF	TNFA_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Schizophrenia

ICD Disease Classification

6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
TNFA messenger RNA (TNF mRNA)	DTT	TNF	7.38E-01	-0.07	-0.16

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3988).
2	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
3	Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther. 2003 Jan;304(1):411-24.
4	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
5	Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
6	Clinical pipeline report, company report or official report of Roche (2009).
7	3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
8	Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
9	The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
10	Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
11	A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
12	ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
13	AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.